NeoPharm (Korea) Market Value
| 092730 Stock | KRW 12,000 90.00 0.74% |
| Symbol | NeoPharm |
NeoPharm 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NeoPharm's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NeoPharm.
| 11/18/2024 |
| 12/18/2024 |
If you would invest 0.00 in NeoPharm on November 18, 2024 and sell it all today you would earn a total of 0.00 from holding NeoPharm LTD or generate 0.0% return on investment in NeoPharm over 30 days. NeoPharm is related to or competes with MegaStudyEdu, DongKook Pharmaceutical, COWELL FASHION, and MegaStudy. ,Ltd. manufactures and sells skin care products in Korea and internationally More
NeoPharm Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NeoPharm's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NeoPharm LTD upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.78 | |||
| Information Ratio | 0.0481 | |||
| Maximum Drawdown | 13.31 | |||
| Value At Risk | (4.40) | |||
| Potential Upside | 5.61 |
NeoPharm Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NeoPharm's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NeoPharm's standard deviation. In reality, there are many statistical measures that can use NeoPharm historical prices to predict the future NeoPharm's volatility.| Risk Adjusted Performance | 0.0591 | |||
| Jensen Alpha | 0.2194 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.0506 | |||
| Treynor Ratio | (0.55) |
NeoPharm LTD Backtested Returns
At this point, NeoPharm is very steady. NeoPharm LTD has Sharpe Ratio of 0.0537, which conveys that the firm had a 0.0537% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for NeoPharm, which you can use to evaluate the volatility of the firm. Please verify NeoPharm's Mean Deviation of 2.23, downside deviation of 2.78, and Risk Adjusted Performance of 0.0591 to check out if the risk estimate we provide is consistent with the expected return of 0.15%. NeoPharm has a performance score of 4 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.36, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NeoPharm are expected to decrease at a much lower rate. During the bear market, NeoPharm is likely to outperform the market. NeoPharm LTD right now secures a risk of 2.84%. Please verify NeoPharm LTD downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if NeoPharm LTD will be following its current price movements.
Auto-correlation | 0.60 |
Good predictability
NeoPharm LTD has good predictability. Overlapping area represents the amount of predictability between NeoPharm time series from 18th of November 2024 to 3rd of December 2024 and 3rd of December 2024 to 18th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NeoPharm LTD price movement. The serial correlation of 0.6 indicates that roughly 60.0% of current NeoPharm price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.6 | |
| Spearman Rank Test | 0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 77.9 K |
NeoPharm LTD lagged returns against current returns
Autocorrelation, which is NeoPharm stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting NeoPharm's stock expected returns. We can calculate the autocorrelation of NeoPharm returns to help us make a trade decision. For example, suppose you find that NeoPharm has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
NeoPharm regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If NeoPharm stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if NeoPharm stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in NeoPharm stock over time.
Current vs Lagged Prices |
| Timeline |
NeoPharm Lagged Returns
When evaluating NeoPharm's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of NeoPharm stock have on its future price. NeoPharm autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, NeoPharm autocorrelation shows the relationship between NeoPharm stock current value and its past values and can show if there is a momentum factor associated with investing in NeoPharm LTD.
Regressed Prices |
| Timeline |
Other Information on Investing in NeoPharm Stock
NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.